ArticleCurrent medicinal chemistry2026
Measuring Health-related Quality of Life in Pediatric Patients with Ultra-rare Diseases: A Multicenter Study.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Characterization, Functional Analysis, Gene Therapy, and Management of Rare Genetic Disorders.Current medicinal chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUltra-rare diseases (URDs) are defined based on point prevalence and are classified as conditions affecting fewer than 1 in 50,000 individuals, and they are more likely to exist among communities with higher consanguinity rates requiring evidence-based data.
methodsIn this multi-center study, we used next-generation sequencing to identify 30 pediatric patients with URDs. Along with the demographic information about their parents, clinical, laboratory, and radiological data was also obtained. Multinomial regression was carried out to assess statistical differences and determine associations using the Quality of Life of Childhood Epilepsy (QOLCE)-55 scale.
resultsThere were 19 male (63.33%) and 11 (36.67%) female patients. Their current age range was 2-15 years (mean=8.83 years). The majority were diagnosed with sodium channelopathy (64.51%). The average Quality of Life (QoL) score of all participants was 51.43 ± 9.01 (reference range 0-100) with quartiles Q1=40, Q2=43.5, and Q3=56.
conclusionWe propose that URDs complicated by epilepsy can significantly impair the QoL of patients and their families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.